Evicenter
MarkdownMedical informationP&T meetings
Descartes-08

Generalized myasthenia gravis

Launch
Not announced
Last updated
177 sources

Clinical evidence

MG-001 phase 1b/2a

73 evidence topics · 7 sources

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Care setting, post-infusion monitoring, premedication, and no lymphodepletion
Study outcomes
Rationale for using safety and tolerability as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Demographics and baseline characteristics by part and arm: all 14 participants
CharacteristicPart 1 (n=3)Part 2 Arm 1, twice weekly (n=3)Part 2 Arm 2, weekly (n=7)Part 2 Arm 3, monthly (n=1)All participants (n=14)
Age, mean (SD), years“57 (16)”View highlighted excerpt for this quote“43 (26)”View highlighted excerpt for this quote“52 (16·8)”View highlighted excerpt for this quote“70”View highlighted excerpt for this quote“52 (18)”View highlighted excerpt for this quote
Female sex, no. (%)“2/3”View highlighted excerpt for this quote“2/3”View highlighted excerpt for this quote“5/7”View highlighted excerpt for this quote“1/1”View highlighted excerpt for this quote“10 (71%)”View highlighted excerpt for this quote
MGFA class II at screening“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“3/7”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“3 (21%)”View highlighted excerpt for this quote
MGFA class III at screening“3/3”View highlighted excerpt for this quote“2/3”View highlighted excerpt for this quote“4/7”View highlighted excerpt for this quote“1/1”View highlighted excerpt for this quote“10 (72%)”View highlighted excerpt for this quote
MGFA class IV at screening“0”View highlighted excerpt for this quote“1/3”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (7%)”View highlighted excerpt for this quote
Duration of disease, median (range), years“13 (5–25)”View highlighted excerpt for this quote“14 (4–15)”View highlighted excerpt for this quote“16 (3–27)”View highlighted excerpt for this quote“26”View highlighted excerpt for this quote“14 (3–27)”View highlighted excerpt for this quote
Anti-AChR antibody“3/3”View highlighted excerpt for this quote“3/3”View highlighted excerpt for this quote“4/7”View highlighted excerpt for this quote“1/1”View highlighted excerpt for this quote“11 (79%)”View highlighted excerpt for this quote
Anti-MuSK antibody“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2/7”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (14%)”View highlighted excerpt for this quote
Seronegative“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1/7”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (7%)”View highlighted excerpt for this quote
Baseline QMG, mean (SD)“14·3 (3·5)”View highlighted excerpt for this quote“17·3 (1·5)”View highlighted excerpt for this quote“15·9 (4·5)”View highlighted excerpt for this quote“8”View highlighted excerpt for this quote“15·3 (4·1)”View highlighted excerpt for this quote
Baseline MG-ADL, mean (SD)“8·7 (3·8)”View highlighted excerpt for this quote“10·7 (3·5)”View highlighted excerpt for this quote“10·7 (3)”View highlighted excerpt for this quote“6”View highlighted excerpt for this quote“10 (3·2)”View highlighted excerpt for this quote
Baseline MGC, mean (SD)“19·3 (6·7)”View highlighted excerpt for this quote“24·7 (4·7)”View highlighted excerpt for this quote“23 (5·2)”View highlighted excerpt for this quote“13”View highlighted excerpt for this quote“21·9 (5·7)”View highlighted excerpt for this quote
Baseline MG-QoL-15r, mean (SD)“23·3 (3·1)”View highlighted excerpt for this quote“19·1 (9)”View highlighted excerpt for this quote“19·7 (5·1)”View highlighted excerpt for this quote“12”View highlighted excerpt for this quote“19·9 (5·8)”View highlighted excerpt for this quote
Prior eculizumab“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2/7”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (14%)”View highlighted excerpt for this quote
Prior rituximab“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2/7”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (14%)”View highlighted excerpt for this quote
Prior IVIg“1/3”View highlighted excerpt for this quote“3/3”View highlighted excerpt for this quote“7/7”View highlighted excerpt for this quote“1/1”View highlighted excerpt for this quote“12 (86%)”View highlighted excerpt for this quote
Prior plasma exchange“0”View highlighted excerpt for this quote“3/3”View highlighted excerpt for this quote“5/7”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“5 (36%)”View highlighted excerpt for this quote
Prior thymectomy“1/3”View highlighted excerpt for this quote“2/3”View highlighted excerpt for this quote“3/7”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“6 (43%)”View highlighted excerpt for this quote
Prior MG crisis requiring intubation“1/3”View highlighted excerpt for this quote“1/3”View highlighted excerpt for this quote“2/7”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“4 (29%)”View highlighted excerpt for this quote
Pyridostigmine at baseline“2/3”View highlighted excerpt for this quote“3/3”View highlighted excerpt for this quote“6/7”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“11 (79%)”View highlighted excerpt for this quote
Prednisone at baseline“3/3”View highlighted excerpt for this quote“2/3”View highlighted excerpt for this quote“5/7”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“10 (71%)”View highlighted excerpt for this quote
Efficacy results
Measures of disease severity at Week 12 by arm and antibody type: Part 2 participants with 12-week follow-up
Measure at Week 12All, n=9 (mean change, 95% CI)Arm 1, n=2 (individual values)Arm 2, n=7 (mean change, 95% CI)AChR+, n=6 (mean change, 95% CI)MuSK+, n=2 (individual values)Seronegative, n=1
MG-ADL“−5·9 [−9, −2·8]”View highlighted excerpt for this quote“−6, −8”View highlighted excerpt for this quote“−6 [−15, +3]”View highlighted excerpt for this quote“−6 [−11, −1]”View highlighted excerpt for this quote“−3, −4”View highlighted excerpt for this quote“−8”View highlighted excerpt for this quote
QMG“−7 [−11, −3]”View highlighted excerpt for this quote“−5, −3”View highlighted excerpt for this quote“−8 [−20, +4]”View highlighted excerpt for this quote“−5 [−10, 0]”View highlighted excerpt for this quote“−9, −5”View highlighted excerpt for this quote“−17”View highlighted excerpt for this quote
MGC“−14 [−19, −9]”View highlighted excerpt for this quote“−7, −11”View highlighted excerpt for this quote“−15 [−29, −1]”View highlighted excerpt for this quote“−14 [−21, −7]”View highlighted excerpt for this quote“−14, −7”View highlighted excerpt for this quote“−22”View highlighted excerpt for this quote
MG-ADL decrease ≥2, No.“8/9”View highlighted excerpt for this quote“2/2”View highlighted excerpt for this quote“6/7”View highlighted excerpt for this quote“5/6”View highlighted excerpt for this quote“2/2”View highlighted excerpt for this quote“1/1”View highlighted excerpt for this quote
MGC decrease ≥3, No.“9/9”View highlighted excerpt for this quote“2/2”View highlighted excerpt for this quote“7/7”View highlighted excerpt for this quote“6/6”View highlighted excerpt for this quote“2/2”View highlighted excerpt for this quote“1/1”View highlighted excerpt for this quote
QMG decrease ≥3, No.“8/9”View highlighted excerpt for this quote“2/2”View highlighted excerpt for this quote“6/7”View highlighted excerpt for this quote“5/6”View highlighted excerpt for this quote“2/2”View highlighted excerpt for this quote“1/1”View highlighted excerpt for this quote
MG-ADL decrease ≥6, No. (post hoc)“5/9”View highlighted excerpt for this quote“2/2”View highlighted excerpt for this quote“3/7”View highlighted excerpt for this quote“4/6”View highlighted excerpt for this quote“0/2”View highlighted excerpt for this quote“1/1”View highlighted excerpt for this quote
Company-reported retreatment analysis: baseline characteristics of the pooled case series, 5 participants
CharacteristicParticipants (n=5)
Age, mean (SD)“58 (12) years”
Age range“49–79”
Women, n (%)“4 (80%)”
AChR+ gMG, n (%)“4 (80%)”
MG-ADL at baseline before initial treatment, mean (SD)“9.2 (3.1)”
MG-ADL at baseline before retreatment, mean (SD)“9.6 (3.4)”
Median interval between end of initial treatment course and first retreatment infusion“16.6 months”; “(range 11.7–22.6)”
Health-related quality of life and patient-reported outcomes
MG-QoL-15r change at Week 12 by arm and antibody type: Part 2 participants with 12-week follow-up
Safety results
Serious adverse events: influenza before treatment, grade 3 urticaria, and myocardial infarction
Adverse events related to Descartes-08 by part and arm: all 14 participants
TermGradePart 1 (n=3)Part 2, all arms (n=11)Part 2 Arm 1 (n=3)Part 2 Arm 2 (n=7)Part 2 Arm 3 (n=1)
Hand numbness“2”View highlighted excerpt for this quote“1/3”View highlighted excerpt for this quoteNot reportedNot reportedNot reportedNot reported
Headache“1”View highlighted excerpt for this quote“1/3”View highlighted excerpt for this quote“5 (45%)”View highlighted excerpt for this quote“1/3”View highlighted excerpt for this quote“3/7”View highlighted excerpt for this quote“1/1”View highlighted excerpt for this quote
Muscle soreness“1”View highlighted excerpt for this quote“1/3”View highlighted excerpt for this quote“1 (9%)”View highlighted excerpt for this quoteNot reported“1/7”View highlighted excerpt for this quoteNot reported
Nausea“1”View highlighted excerpt for this quote“1/3”View highlighted excerpt for this quote“4 (36%)”View highlighted excerpt for this quote“2/3”View highlighted excerpt for this quote“2/7”View highlighted excerpt for this quoteNot reported
Rash“3”View highlighted excerpt for this quoteNot reported“1 (9%)”View highlighted excerpt for this quote“1/3”View highlighted excerpt for this quoteNot reportedNot reported
Itchy throat“1”View highlighted excerpt for this quoteNot reported“2 (18%)”View highlighted excerpt for this quoteNot reported“1/7”View highlighted excerpt for this quote“1/1”View highlighted excerpt for this quote
Vomiting“1”View highlighted excerpt for this quoteNot reported“3 (27%)”View highlighted excerpt for this quote“2/3”View highlighted excerpt for this quote“1/7”View highlighted excerpt for this quoteNot reported
Weakness“1”View highlighted excerpt for this quoteNot reported“2 (18%)”View highlighted excerpt for this quote“2/3”View highlighted excerpt for this quoteNot reportedNot reported
Line infiltration“1”View highlighted excerpt for this quoteNot reported“1 (9%)”View highlighted excerpt for this quote“1/3”View highlighted excerpt for this quoteNot reportedNot reported
Fever“1”View highlighted excerpt for this quoteNot reported“4 (36%)”View highlighted excerpt for this quote“1/3”View highlighted excerpt for this quote“3/7”View highlighted excerpt for this quoteNot reported
Shortness of breath“1”View highlighted excerpt for this quoteNot reported“2 (18%)”View highlighted excerpt for this quote“1/3”View highlighted excerpt for this quote“1/7”View highlighted excerpt for this quoteNot reported
Chills“1”View highlighted excerpt for this quoteNot reported“2 (18%)”View highlighted excerpt for this quote“1/3”View highlighted excerpt for this quote“1/7”View highlighted excerpt for this quoteNot reported
Diarrhea“1”View highlighted excerpt for this quoteNot reported“1 (9%)”View highlighted excerpt for this quote“1/3”View highlighted excerpt for this quote“1/7”View highlighted excerpt for this quoteNot reported
Gum inflammation“1”View highlighted excerpt for this quoteNot reported“1 (9%)”View highlighted excerpt for this quoteNot reported“1/7”View highlighted excerpt for this quoteNot reported
Teeth sensitivity“1”View highlighted excerpt for this quoteNot reported“1 (9%)”View highlighted excerpt for this quoteNot reported“1/7”View highlighted excerpt for this quoteNot reported
Night sweats“1”View highlighted excerpt for this quoteNot reported“1 (9%)”View highlighted excerpt for this quoteNot reported“1/7”View highlighted excerpt for this quoteNot reported
Restless leg“1”View highlighted excerpt for this quoteNot reported“1 (9%)”View highlighted excerpt for this quoteNot reported“1/7”View highlighted excerpt for this quoteNot reported
Lightheadedness“1”View highlighted excerpt for this quoteNot reported“1 (9%)”View highlighted excerpt for this quoteNot reported“1/7”View highlighted excerpt for this quoteNot reported
Company-reported retreatment analysis: safety events after initial treatment and retreatment, 5 participants
Safety eventInitial treatment (n=5)Retreatment (n=5)
Serious adverse events“1”“0”
Infusion-related reaction“16/30 infusions”“17/30 infusions”
Infusion-related reaction, grade 1“10”“12”
Infusion-related reaction, grade 2“6”“5”
Tachycardia“1”“5”
CRS“0”“0”
ICANS“0”“0”
Cytopenias“0”“0”
Hypogammaglobulinemia“0”“0”
Study limitations
Summary
  • Design: the study was open label, nonrandomized, and without a control arm, and the authors state that a placebo effect cannot be excluded and that comparison with historical controls is not conclusive. Part 2 participants were assigned to dosing arms at the investigator's discretion, taking participant preference into account.
  • Sample size: 14 participants were enrolled (3 in Part 1 and 11 in Part 2), and no formal power analysis was performed. The week 12 efficacy analysis included 9 Part 2 participants, and only 2 participants had MuSK antibody-positive disease and 1 had seronegative disease. Three participants had MGFA class II disease, which the authors note may improve to minimum symptom expression with conventional treatment.
  • Endpoints: efficacy measures were secondary endpoints with no prespecified primary efficacy time point, and the analysis of MG-ADL decreases of 6 points or more was post hoc. Corticosteroid tapering was permitted after week 4 at the investigator's discretion, and the authors state that an effect of the unchanged maintenance dose cannot be excluded in the absence of a control arm.
  • Follow-up and attrition: median follow-up in Part 2 was 5 months (range 3 to 9) in the initial report. By week 16 all twice-weekly arm participants were off study (adverse event, n = 1; worsening symptoms, n = 2), and the single monthly-arm participant withdrew after 3 of 6 infusions. The 12-month analysis is limited to the 7 weekly-arm participants, of whom 5 maintained clinically meaningful improvement at month 12.
  • Retreatment and biomarkers: the authors state that more experience with initial treatment and retreatment is needed, that allergic reactions including anaphylaxis cannot be excluded, and that circulating antibody titers may not reflect tissue concentrations. The pooled retreatment case series of 5 participants is company-reported.
  • Reporting: the sponsor took part in the design, data collection, interpretation, analysis, manuscript writing, and decision to submit. The text gives the most common treatment-related adverse events in Part 2 as 5 (45%), 4 (36%), and 4 (36%) “of 14 patients”, while the table reports these counts for Part 2 (n = 11). The month-12 MG-QoL-15r change is printed as “−7.7 [−15.6 to −8.4]”, an interval that does not contain its point estimate.
Small, open-label, uncontrolled design: author-stated limitations